Our Blog

Rare disease commercialization requires precision. Learn how Rare Pharmacy helps manufacturers reduce risk from launch through lifecycle management.

Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch.

Austin Russian discusses the advantages and challenges of manufacturers taking a more active role in the patient journey, as well as how rare disease and cell and gene therapy launches are evolving.

Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.

Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. For 2025, DCI has identified more...

PANTHERx Rare’s CEO, Bansi Nagji, authored an insightful guest post for Drug Channels Institute titled, “The Rare Journey Needs a Special Pharmacy Partner.” He makes...

Next week, the Drug Channels Institute (DCI) will release our 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This 17th edition provides our most...

Communication gaps, preventable delays and limited support place significant responsibility on patients on the rare disease journey, a new survey finds. The survey (PDF) was...

In this Drug Channels Institute guest post, “Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different,” PANTHERx’s Chief Commercial & Clinical Officer, Dr. Richard...

Dr. Richard Faris, our Chief Commercial and Clinical Officer, recently submitted a proposal on behalf of PANTHERx in response to the FDA’s request for public...